These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 18408506)
1. Older antibiotic gains new respect as potent treatment for tuberculosis. Rifapentine is already approved for use with humans. Nuermberger E Home Healthc Nurse; 2008 Apr; 26(4):204-5. PubMed ID: 18408506 [No Abstract] [Full Text] [Related]
2. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration. Roehr B J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728 [TBL] [Abstract][Full Text] [Related]
6. Rifapentine: its role in the treatment of tuberculosis. Temple ME; Nahata MC Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321 [TBL] [Abstract][Full Text] [Related]
7. [An update on the antibiotic therapy of tuberculosis]. Rossi G Recenti Prog Med; 1999 May; 90(5):241-3. PubMed ID: 10380549 [No Abstract] [Full Text] [Related]
8. Experimental and clinical study on the antituberculous activity of tuberactinomycin-N, a new antibiotic. Toyoara M Bull Int Union Tuberc; 1974 Aug; 49 suppl 1():288-91. PubMed ID: 4468026 [No Abstract] [Full Text] [Related]
9. Saquinavir and rifampicin for tuberculosis and AIDS: new considerations. Torres TS; Rolla VC Int J Tuberc Lung Dis; 2006 Nov; 10(11):1302; author reply 1302-3. PubMed ID: 17131794 [No Abstract] [Full Text] [Related]
10. Management of tuberculosis. Fantry LE N Engl J Med; 2001 Nov; 345(20):1501-2. PubMed ID: 11794208 [No Abstract] [Full Text] [Related]
11. Rifapentine for the treatment of pulmonary tuberculosis. Munsiff SS; Kambili C; Ahuja SD Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024 [TBL] [Abstract][Full Text] [Related]
12. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Guglielmetti L; Günther G; Leu C; Cirillo D; Duarte R; Garcia-Basteiro AL; Goletti D; Jankovic M; Kuksa L; Maurer FP; Méchaï F; Tiberi S; van Leth F; Veziris N; Lange C; ; Eur Respir J; 2022 May; 59(5):. PubMed ID: 35589114 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough? Zheng C; Hu X; Zhao L; Hu M; Gao F Drug Des Devel Ther; 2017; 11():2957-2968. PubMed ID: 29066867 [TBL] [Abstract][Full Text] [Related]
15. Rifapentine--a long-acting rifamycin for tuberculosis. Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594 [No Abstract] [Full Text] [Related]
16. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin. Goldberg SV; Hanson D; Peloquin CA Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149 [No Abstract] [Full Text] [Related]
17. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094 [TBL] [Abstract][Full Text] [Related]
18. New approaches to the treatment of latent tuberculosis. Sterling TR Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686 [TBL] [Abstract][Full Text] [Related]
19. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Chan JG; Tyne AS; Pang A; Chan HK; Young PM; Britton WJ; Duke CC; Traini D Pharm Res; 2014 May; 31(5):1239-53. PubMed ID: 24242939 [TBL] [Abstract][Full Text] [Related]
20. [Studies on tuberactinomycin-N. Report 3. Comparison of the effects of TUM-N and INH on experimental mouse tuberculosis (author's transl)]. Shimizu T; Yokoyama M; Yoshida U; Onuma H; Narita A Kekkaku; 1977 Jan; 52(1):21-7. PubMed ID: 839648 [No Abstract] [Full Text] [Related] [Next] [New Search]